Atlas Arteria 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Hugh Wehby

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	1.6yrs

최근 관리 업데이트

Recent updates

Is Now An Opportune Moment To Examine Atlas Arteria Limited (ASX:ALX)?

Apr 07

What Does Atlas Arteria Limited's (ASX:ALX) Share Price Indicate?

Dec 22

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 43% Undervaluation?

Aug 10

Is Atlas Arteria (ASX:ALX) Using Too Much Debt?

May 31

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 48% Undervaluation?

Apr 14

Debra Goodin Is The Independent Chairman of the Board of Atlas Arteria Limited (ASX:ALX) And They Just Picked Up 54% More Shares

Mar 03

Here's Why Atlas Arteria (ASX:ALX) Can Afford Some Debt

Feb 27

Atlas Arteria (ASX:ALX) Has Compensated Shareholders With A Respectable 78% Return On Their Investment

Jan 31

Atlas Arteria Limited (ASX:ALX) Shares Could Be 44% Below Their Intrinsic Value Estimate

Dec 27

How Many Atlas Arteria Limited (ASX:ALX) Shares Do Institutions Own?

Dec 06

Is There Now An Opportunity In Atlas Arteria Limited (ASX:ALX)?

Nov 19

Atlas Arteria (ASX:ALX) Has Gifted Shareholders With A Fantastic 142% Total Return On Their Investment

Jul 30

CEO

Hugh Wehby (40 yo)

less than a year

테뉴어

Mr. Hugh Wehby, BEc (Hons), DipInvRel, has been the Chief Executive Officer, Managing Director and Director of Atlas Arteria Limited since November 18, 2024. He was Chief Commercial Officer of Transurban G...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Collins	Chief Financial Officer	2.3yrs	AU$1.18m	0.00073% A$ 50.3k
Vincent Portal-Barrault	Chief Operating Officer	5.7yrs	AU$1.59m	0.0079% A$ 546.5k
Hugh Wehby	CEO, MD & Director	less than a year	데이터 없음	데이터 없음
Tess Palmer	Director of Investor Relations	no data	데이터 없음	데이터 없음
Clayton McCormack	Company Secretary & General Counsel	5.7yrs	데이터 없음	데이터 없음
Navleen Prasad	Public Affairs Manager	no data	데이터 없음	데이터 없음
Jim Dickson	Corporate Development & Strategy Executive	no data	데이터 없음	데이터 없음
Catherine Brain	Group Executive of People & Culture	no data	데이터 없음	데이터 없음
Paul Lynch	Joint Company Secretary	3.3yrs	데이터 없음	데이터 없음
Ryan Reynolds	Specialist of Forecasting and Analysis	no data	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

경험이 풍부한 관리: ALX 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hugh Wehby	CEO, MD & Director	less than a year	데이터 없음	데이터 없음
Jean-Georges Malcor	Independent Non-Executive Director	6.1yrs	AU$185.00k	0.0031% A$ 216.4k
David Bartholomew	Independent Non Executive Director	6.2yrs	AU$185.00k	0.0022% A$ 150.2k
Laura Hendricks	Independent Non-Executive Director	1.2yrs	AU$39.37k	데이터 없음
Debra Goodin	Independent Non-Executive Chairman	7.3yrs	AU$310.00k	0.0067% A$ 461.0k
Kiernan Bell	Independent Non-executive Director	1.3yrs	데이터 없음	0.00021% A$ 14.5k
Danny Elia	Non-Executive Director	less than a year	데이터 없음	데이터 없음
John Wigglesworth	Independent Non-Executive Director	1.9yrs	AU$185.00k	0.0019% A$ 133.7k
Kenneth Daley	Non-Executive Director	1.6yrs	AU$91.61k	0.00069% A$ 47.6k

1.6yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: ALX 의 이사회는 경험(평균 재직 기간 1.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/31 09:39
장 마감 주가	2024/12/31 00:00
수익	2024/06/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Atlas Arteria Limited 21 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Russell Wright	Barclay Pearce Capital Pty Limited
Benjamin Brayshaw	Barrenjoey Markets Pty Limited
Matthew Ryan	Barrenjoey Markets Pty Limited

Atlas Arteria 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

High number of new directors

Atlas Arteria Limited Appoints Hugh Wehby as Managing Director

Atlas Arteria Limited Announces the Retirement of Graeme Bevans as CEO and Managing Director

Atlas Arteria Limited, Annual General Meeting, May 15, 2024

Atlas Arteria Limited, Annual General Meeting, May 16, 2024

Atlas Arteria Appoints Laura Hendricks to the Board as an Independent Non-Executive Director

Recent updates

First half dividend of AU$0.20 announced

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2024, Payable on 7 October 2024

High number of new directors

Consensus revenue estimates fall by 13%

First half 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Atlas Arteria Limited Appoints Hugh Wehby as Managing Director

Atlas Arteria Limited to Report First Half, 2025 Results on Aug 28, 2025

Final dividend of AU$0.20 announced

Atlas Arteria Limited Announces the Retirement of Graeme Bevans as CEO and Managing Director

Atlas Arteria Limited Announces Distribution for the Six Months Ended 31 December 2023, Payable on 8 April 2024

Atlas Arteria Limited, Annual General Meeting, May 15, 2024

Atlas Arteria Limited, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: AU$0.22 (vs AU$0.25 in FY 2022)

Atlas Arteria Appoints Laura Hendricks to the Board as an Independent Non-Executive Director

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2023, Estimated Payment Date Is 5 October 2023

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2023, Payable on 5 October 2023

Consensus EPS estimates fall by 11%

First half 2023 earnings released: EPS: AU$0.12 (vs AU$0.13 in 1H 2022)

Atlas Arteria Limited Reaffirms Distribution Guidance for the First Half and Second Half of 2023

Atlas Arteria Limited to Report First Half, 2024 Results on Aug 29, 2024

Atlas Arteria Limited Appoints Ken Daley as Director

Atlas Arteria Limited Announces Caroline Foulger Will Retire as A Director, with Effect from 1 July 2023

Consensus EPS estimates fall by 15%

Full year 2022 earnings released: EPS: AU$0.25 (vs AU$0.19 in FY 2021)

Insufficient new directors

Atlas Arteria Limited Announces Board Changes

Atlas Arteria Limited (ASX:ALX) completed the acquisition of 66.67% stake in Skyway Concession Company, LLC from CPP Investments and OMERS Infrastructure.

Now 20% undervalued after recent price drop

Atlas Arteria Limited, Annual General Meeting, Apr 27, 2023

Consensus revenue estimates increase by 10%

Atlas Arteria Limited to Report Q4, 2022 Results on Feb 23, 2023

Price target decreased to AU$6.96

Investor sentiment deteriorated over the past week

Atlas Arteria Limited Provides Distribution Guidance for the Year 2023

Atlas Arteria Limited (ASX:ALX) entered into an agreement to acquire a 66.67% stake in Skyway Concession Company, LLC for $2 billion.

Consensus EPS estimates fall by 14%

First half 2022 earnings released: EPS: AU$0 (vs AU$0.074 in 1H 2021)

Atlas Arteria Limited Provides Dividend Guidance for the First Half of 2022

Price target increased to AU$7.40

Investor sentiment improved over the past week

Atlas Arteria Limited Announces Executive Changes

Is Now An Opportune Moment To Examine Atlas Arteria Limited (ASX:ALX)?

Independent Non-Executive Director recently bought AU$76k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

What Does Atlas Arteria Limited's (ASX:ALX) Share Price Indicate?

Insider recently bought AU$67k worth of stock

First half 2021 earnings released: EPS AU$0.074 (vs AU$0.14 loss in 1H 2020)

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 43% Undervaluation?

Is Atlas Arteria (ASX:ALX) Using Too Much Debt?

Price target decreased to AU$6.21

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 48% Undervaluation?

Debra Goodin Is The Independent Chairman of the Board of Atlas Arteria Limited (ASX:ALX) And They Just Picked Up 54% More Shares

Independent Chairman of the Board recently bought AU$100k worth of stock

Here's Why Atlas Arteria (ASX:ALX) Can Afford Some Debt

Full year 2020 earnings released: AU$0.061 loss per share (vs AU$0.024 profit in FY 2019)

Atlas Arteria Limited Announces Board Changes

New 90-day low: AU$5.97

Atlas Arteria Limited to Report Fiscal Year 2020 Results on Feb 25, 2021

Atlas Arteria (ASX:ALX) Has Compensated Shareholders With A Respectable 78% Return On Their Investment

Atlas Arteria Limited, Annual General Meeting, Apr 27, 2021

Atlas Arteria Limited (ASX:ALX) Shares Could Be 44% Below Their Intrinsic Value Estimate

How Many Atlas Arteria Limited (ASX:ALX) Shares Do Institutions Own?

Is There Now An Opportunity In Atlas Arteria Limited (ASX:ALX)?

Atlas Arteria Limited Announces Changes to its Board

New 90-day low: AU$5.95

New 90-day low: AU$6.07

New 90-day low - AU$6.10

Atlas Arteria Limited (ASX:ALX) acquired 6.14% stake in APRR and ADALEC from Macquarie European Infrastructure Fund II managed by Macquarie Infrastructure and Real Assets (Europe) Limited.